Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 12, 2023

BUY
$0.55 - $1.0 $1 - $2
2 Added 0.0%
74,750 $44,000
Q4 2022

Feb 13, 2023

BUY
$0.52 - $0.77 $2 - $3
5 Added 0.01%
74,748 $57,000
Q3 2022

Nov 14, 2022

BUY
$0.29 - $0.53 $20 - $38
72 Added 0.1%
74,743 $22,000
Q2 2022

Aug 12, 2022

BUY
$0.3 - $1.67 $7,438 - $41,409
24,796 Added 49.72%
74,671 $35,000
Q1 2022

May 16, 2022

BUY
$1.61 - $2.5 $1 - $2
1 Added 0.0%
49,875 $80,000
Q4 2021

Feb 14, 2022

BUY
$2.3 - $4.71 $114,268 - $234,002
49,682 Added 25876.04%
49,874 $119,000
Q3 2021

Nov 15, 2021

SELL
$3.36 - $4.79 $10 - $14
-3 Reduced 1.54%
192 $1,000
Q1 2021

May 13, 2021

BUY
$3.8 - $8.04 $741 - $1,567
195 New
195 $1,000

Others Institutions Holding ACOR

# of Institutions
1
Shares Held
133K
Call Options Held
0
Put Options Held
0

About ACORDA THERAPEUTICS INC


  • Ticker ACOR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 24,338,400
  • Market Cap $6.33M
  • Description
  • Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also...
More about ACOR
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.